Blackard C E
Cancer Chemother Rep. 1975 Jan-Feb;59(1):225-7.
The Veterans' Administration Cooperative Urological Research Group has conducted three consecutive randomized clinical trials of various treatments for all stages of prostatic carcinoma. Thus far, a total of 3774 patients have been entered into these three main studies. The first study showed that early endocrine treatment of patients with advanced prostatic cancer did not increase overall survival when compared to initial treatment with placebo alone. Diethylstilbestrol, when given in a dose of 5.0 mg/day, was associated with an increased incidence of cardiovascular deaths. In the second study, diethylstilbestrol given in a dose of 1.0 mg/day has been as effective as the 5.0-mg dose in controlling the prostatic carcinoma but has been associated with a lower incidence of cardiovascular deaths. Patients are still being entered into the third study and it is too early to report the findings in detail.
退伍军人管理局合作泌尿外科研究小组对前列腺癌各阶段的多种治疗方法进行了连续三项随机临床试验。迄今为止，共有3774名患者参与了这三项主要研究。第一项研究表明，与仅用安慰剂进行初始治疗相比，晚期前列腺癌患者的早期内分泌治疗并未提高总体生存率。己烯雌酚每日剂量为5.0毫克时，心血管死亡发生率增加。在第二项研究中，每日剂量为1.0毫克的己烯雌酚在控制前列腺癌方面与5.0毫克剂量同样有效，但心血管死亡发生率较低。仍有患者在参与第三项研究，详细报告研究结果为时尚早。
